Sandra M Swain

Summary

Country: USA

Publications

  1. ncbi A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer
    Peter F Lebowitz
    Medical Oncology Clinical Research Unit, Cancer Therapeutics Branch, Laboratory of Pathology, Biostatistics and Data Management, and Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6764-9. 2004
  2. ncbi Emerging drugs to replace current leaders in first-line therapy for breast cancer
    Michael C Cox
    National Cancer Institute National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA
    Expert Opin Emerg Drugs 11:489-501. 2006
  3. ncbi Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Clin Adv Hematol Oncol 6:455-67. 2008
  4. pmc Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5893-9. 2008
  5. ncbi Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, D C, USA Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines Mount Vernon Cancer Centre, Middlesex, United Kingdom Roche Products Ltd, Welwyn Garden City, United Kingdom Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York, USA
    Oncologist 19:693-701. 2014
  6. ncbi Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
    S M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington
    Ann Oncol 25:1116-21. 2014
  7. pmc Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC 20010, USA
    Oncologist 18:257-64. 2013
  8. ncbi Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC 20010, USA
    Lancet Oncol 14:461-71. 2013
  9. pmc Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Washington Cancer Institute at Washington Hospital Center, Washington, DC 20010, USA
    N Engl J Med 362:2053-65. 2010
  10. doi Chemotherapy: updates and new perspectives
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    Oncologist 16:30-9. 2011

Detail Information

Publications64

  1. ncbi A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer
    Peter F Lebowitz
    Medical Oncology Clinical Research Unit, Cancer Therapeutics Branch, Laboratory of Pathology, Biostatistics and Data Management, and Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6764-9. 2004
    ..This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer...
  2. ncbi Emerging drugs to replace current leaders in first-line therapy for breast cancer
    Michael C Cox
    National Cancer Institute National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA
    Expert Opin Emerg Drugs 11:489-501. 2006
    ..These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease...
  3. ncbi Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Clin Adv Hematol Oncol 6:455-67. 2008
    ..This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone...
  4. pmc Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5893-9. 2008
    ..To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD)...
  5. ncbi Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, D C, USA Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines Mount Vernon Cancer Centre, Middlesex, United Kingdom Roche Products Ltd, Welwyn Garden City, United Kingdom Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York, USA
    Oncologist 19:693-701. 2014
    ....
  6. ncbi Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
    S M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington
    Ann Oncol 25:1116-21. 2014
    ..We carried out exploratory analyses of the incidence and time to development of central nervous system (CNS) metastases in patients from CLEOPATRA...
  7. pmc Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC 20010, USA
    Oncologist 18:257-64. 2013
    ..We report cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel observed in the phase III study CLEOPATRA in patients with HER2-positive first-line metastatic breast cancer (MBC)...
  8. ncbi Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC 20010, USA
    Lancet Oncol 14:461-71. 2013
    ..Interim analysis of overall survival favoured the pertuzumab group but was not significant. Here, we report results for overall survival after an additional year of follow-up...
  9. pmc Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Washington Cancer Institute at Washington Hospital Center, Washington, DC 20010, USA
    N Engl J Med 362:2053-65. 2010
    ..The effectiveness of concurrent versus sequential regimens is not known...
  10. doi Chemotherapy: updates and new perspectives
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    Oncologist 16:30-9. 2011
    ..This paper discusses recent data, including new trials that are more fully incorporating current knowledge with respect to molecular markers and the underlying biology of breast cancer...
  11. doi Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Breast Cancer Res Treat 113:315-20. 2009
    ..These results can be used to inform premenopausal women about the risk and time course of amenorrhea associated with this common adjuvant therapy regimen, along with the effects on symptoms and QOL...
  12. doi Chemotherapy: updates and new perspectives
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    Oncologist 15:8-17. 2010
    ..This paper discusses recent data, including new trials that are more fully incorporating current knowledge with respect to molecular markers and the underlying biology of breast cancer...
  13. pmc Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial
    Patricia A Ganz
    National Surgical Adjuvant Breast and Bowel Project Operations Center NSABP, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 29:1110-6. 2011
    ..The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes...
  14. doi Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
    Andre Robidoux
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA Centre Hospitalier de l Université de Montréal, Montreal, QC, Canada Electronic address
    Lancet Oncol 14:1183-92. 2013
    ....
  15. pmc Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
    Sandra M Swain
    Sandra M Swain, Gong Tang, Charles E Geyer Jr, Priya Rastogi, James N Atkins, Paul P Donnellan, Louis Fehrenbacher, Catherine A Azar, André Robidoux, Jonathan A Polikoff, Adam M Brufsky, David D Biggs, Edward A Levine, John L Zapas, Louise Provencher, Soonmyung Paik, Joseph P Costantino, Eleftherios P Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project NSABP Norman Wolmark, Allegheny General Hospital, Allegheny Health Network Gong Tang and Joseph P Costantino, NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health Priya Rastogi, University of Pittsburgh Cancer Institute Adam M Brufsky, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA Sandra M Swain, Medstar Washington Hospital Center, Washington, DC Charles E Geyer Jr, Virginia Commonwealth University, Richmond, VA James N Atkins, UCLA-SFVP Department of Medicine
    J Clin Oncol 31:3197-204. 2013
    ....
  16. pmc Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal gr
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
    J Clin Oncol 30:3792-9. 2012
    ..Given the demonstrated efficacy of trastuzumab, ongoing assessment of cardiac safety and identification of risk factors for CD are important for optimal patient care...
  17. ncbi Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines...
  18. doi Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    Priya Rastogi
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 11:228-34. 2011
    ..The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC)...
  19. pmc Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
    D Craig Allred
    National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
    J Clin Oncol 30:1268-73. 2012
    ..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen...
  20. ncbi Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
    Javier Cortes
    aVall d Hebron University Hospital, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain bMedStar Washington Hospital Center, Washington Cancer Institute, Washington, District of Columbia cMid Ohio Oncology Hematology Inc, The Mark H Zangmeister Center, Columbus, Ohio dGenentech, South San Francisco, California eMemorial Sloan Kettering Cancer Center, New York, New York, USA fRiga East University Hospital Oncology Center, Riga, Latvia gDaugavpils Re and gacute ionālā Slimnīca, Daugavpils, Latvia hGesundheitszentrum Fricktal, Spital Rheinfelden and Laufenburg, Rheinfelden, Switzerland iNational Hospital Organization Osaka National Hospital, Osaka City, Osaka, Japan jRoche Products Limited, Welwyn Garden City, UK kPharsight, Montreal, Quebec, Canada
    Anticancer Drugs 24:1084-92. 2013
    ..In conclusion, no PK DDI was observed when pertuzumab, trastuzumab, and docetaxel were combined for the treatment of HER2-positive metastatic breast cancer. ..
  21. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  22. ncbi A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K Dennison
    Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
    Invest New Drugs 25:545-51. 2007
    ..The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone...
  23. pmc Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31
    Katherine L Pogue-Geile
    Affiliations of authors National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA J HJ, HB, PR, LF, EHR, SMS, EPM, DLW, CEG, Jr, JPC, NW, SP Division of Pathology, NSABP KLP G, CK, NT, PGG, DF, YT, OLB, AL, S IK, MLR, MYR, NLB, S RK, ZDH Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA J HJ, HB, JPC PhenoPath Laboratories, PLLC, Seattle, Germany
    J Natl Cancer Inst 105:1782-8. 2013
    ..This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31...
  24. doi Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
    Alexander H G Paterson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet Oncol 13:734-42. 2012
    ..The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary breast cancer...
  25. doi The impact of systemic therapy following ductal carcinoma in situ
    Jennifer Eng-Wong
    Department of Internal Medicine, Division of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    J Natl Cancer Inst Monogr 2010:200-3. 2010
    ..We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies...
  26. ncbi Cardiovascular complications of breast cancer therapy
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Clin Adv Hematol Oncol 6:247-8, 282. 2008
  27. doi Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer
    Paul H Levine
    George Washington University School of Public Health and Health Services, Washington, DC 20037, USA
    Clin Breast Cancer 12:232-9. 2012
    ..Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that on presentation resembles locally advanced breast cancer (LABC). This study identified molecular features of IBC and LABC to investigate pathogenesis...
  28. ncbi The heart of the matter
    Chia C Portera
    J Clin Oncol 25:3794-6. 2007
  29. ncbi Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience
    Arpi Thukral
    Medical Oncology Branch, Molecular Imaging Program, and Biostatistics and Data Management Section, Center for Cancer Research, NCI, and Diagnostic Radiology Department, Warren G Magnuson Clinical Center, NIH, Bethesda, MD 20889 5015, USA
    Radiology 244:727-35. 2007
    ....
  30. ncbi Circulating biomarkers of bevacizumab activity in patients with breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
    Cancer Biol Ther 7:15-20. 2008
    ..Tumor samples were evaluated for VEGFR-2 mutations before and after bevacizumab...
  31. doi Cardiac toxicity in breast cancer survivors: review of potential cardiac problems
    Brian R J Healey Bird
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, MD, USA
    Clin Cancer Res 14:14-24. 2008
    ..This review examines the cardiac toxicity of adjuvant therapy, monitoring for early changes and existing guidelines for monitoring cardiac function in patients with breast cancer...
  32. doi Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
    Julia D Wulfkuhle
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
    J Proteome Res 7:1508-17. 2008
    ..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis...
  33. doi Locally advanced and inflammatory breast cancer
    Stephen Chia
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada
    J Clin Oncol 26:786-90. 2008
  34. ncbi Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
    ....
  35. doi Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer
    Chia C Portera
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 14:2710-6. 2008
    ..To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy...
  36. ncbi A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer
    Matthew L Goldman
    Breast Cancer Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    Oncology 71:306-8. 2006
    ..This case demonstrates that patients with a torus palatinus may be at high risk for osteonecrosis, and reinforces the need for good oral hygiene and frequent dental examination while receiving bisphosphonate therapy...
  37. ncbi Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
    J Clin Oncol 25:3421-7. 2007
    ..Ixabepilone was evaluated for efficacy and safety in a phase II clinical trial for women with metastatic breast cancer...
  38. ncbi Contralateral breast cancer: where does it all begin?
    Suparna Bonthala Wedam
    J Clin Oncol 23:4585-7. 2005
  39. ncbi Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889 5015, USA
    J Clin Oncol 22:4067-74. 2004
    ..To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy...
  40. ncbi Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 10:5038-47. 2004
    ..The purpose of this study was to determine the toxicities and characterize the pharmacokinetics of docetaxel and flavopiridol in patients with metastatic breast cancer...
  41. ncbi Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
    Antoinette R Tan
    Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20889, USA
    J Clin Oncol 22:3080-90. 2004
    ....
  42. ncbi Ductal carcinoma in situ, complexities and challenges
    Gregory D Leonard
    Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889 5105, USA
    J Natl Cancer Inst 96:906-20. 2004
    ..Ongoing and recently completed studies should provide information on outcomes in patients treated with lumpectomy alone and on the effectiveness of aromatase inhibitors as an alternative to tamoxifen...
  43. ncbi CA 125 elevation in breast cancer: a case report and review of the literature
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Breast J 10:146-9. 2004
    ..Further information on CA 125 in breast cancer is required to delineate its role in the management of this disease...
  44. ncbi Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 4:S121-6. 2004
    ..These trials will be important in establishing a role for this agent in the adjuvant setting and will hopefully lead to the development of more effective adjuvant chemotherapy regimens in the future...
  45. ncbi Ongoing adjuvant trials with trastuzumab in breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889, USA
    Semin Oncol 30:54-64. 2003
    ..For now, the use of trastuzumab as adjuvant therapy is still investigational, but its integration has tremendous potential to improve treatment outcomes in patients with primary breast cancer...
  46. ncbi Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
    Erin R Lepper
    Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, and Cancer Therapeutics Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 796:181-8. 2003
    ..2% and 2.13 to 5.10%, respectively, for three different sets of quality control samples. The developed method was successfully applied to study the pharmacokinetics of erlotinib in a cancer patient at the recommended daily dose of 150 mg...
  47. ncbi Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
    Nicole J McCarthy
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 8:3857-62. 2002
    ....
  48. ncbi Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
    Antoinette R Tan
    Center for Cancer Research, Developmental Therapeutics Program, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 20:4074-82. 2002
    ..To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as a daily 1-hour infusion every 3 weeks...
  49. ncbi Oophorectomy in carriers of BRCA mutations
    Sen H Zhuang
    N Engl J Med 347:1037-40; author reply 1037-40. 2002
  50. ncbi Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889 5015, USA
    J Clin Oncol 23:2726-34. 2005
    ..In a phase II trial, we evaluated the efficacy and safety of ixabepilone in women with metastatic and locally advanced breast cancer...
  51. ncbi Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer
    Sherry X Yang
    Cancer Therapeutics Branch in Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 11:6226-32. 2005
    ....
  52. ncbi A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20889, USA
    Clin Breast Cancer 6:535-9. 2006
  53. ncbi Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    J Clin Oncol 24:5769-79. 2006
    ....
  54. ncbi Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889 5015, USA
    Invest New Drugs 25:63-7. 2007
    ..Although ixabepilone was well-tolerated, the dose of 8-10 mg/m(2) daily for 3 days is not an effective therapy in metastatic breast cancer previously exposed to taxanes...
  55. ncbi Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel
    Michael C Cox
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 12:4636-40. 2006
    ..This study examines the influence of garlic supplementation on the pharmacokinetics of docetaxel, a CYP3A4 substrate...
  56. ncbi Clinical aspects of inflammatory breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Centre for Cancer Research, National Cancer Institute, National Institute of Health, MD 20889, USA
    Breast Dis 22:35-44. 2005
    ..This review addresses the historical milestones and clinical characteristics involved in the differentiation of IBC and briefly discusses the emerging molecular data that may facilitate the distinction of IBC from LABC...
  57. ncbi A step in the right direction
    Sandra M Swain
    J Clin Oncol 24:3717-8. 2006
  58. ncbi Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone
    James J Lee
    Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program, National Institutes of Health, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:2084-91. 2006
    ....
  59. ncbi Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
    Suparna Bonthala Wedam
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 8901 Wisconsin Avenue, Building 8, Rm 5101, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:769-77. 2006
    ..Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, was administered to previously untreated patients to evaluate parameters of angiogenesis...
  60. ncbi Aromatase inhibitors--a triumph of translational oncology
    Sandra M Swain
    N Engl J Med 353:2807-9. 2005
  61. ncbi A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Clin Breast Cancer 6:460-3. 2005
  62. ncbi Concepts and clinical trials of dose-dense chemotherapy for breast cancer
    Jennifer A Orzano
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Department of Health and Human Services, Bethesda, MD, USA
    Clin Breast Cancer 6:402-11. 2005
    ..The strengths and limitations of CALGB 9741 will then be discussed before the presentation of future directions of research and recommendations for clinical practice today...
  63. ncbi Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
    James J Lee
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889 5015, USA
    Semin Oncol 32:S22-6. 2005
    ..The development of these novel agents may evade MDR and may improve the outcome of patients with breast cancer...
  64. ncbi Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD20889, USA
    Semin Oncol 29:77-85. 2002
    ..The interruption of the cell cycle through modulation of CDKs with an agent such as flavopiridol has potential therapeutic efficacy, especially in combination with chemotherapy...